Novel S1P-Based Therapeutics to Improve Outcomes and Reduce Disability in Patients with Relapsing Multiple Sclerosis


Program Dates: April 10th, 2020 - April 9th, 2021
Credits: 1.0 AMA PRA Category 1 Credit™


Novel S1P-Based Therapeutics to Improve Outcomes and Reduce Disability in Patients with Relapsing Multiple Sclerosis

Program Overview

This CME program, derived from content presented at the Advanced Curriculum for Multiple Sclerosis 2020 Course in West Palm Beach, Florida, will highlight novel S1P-based therapeutics to improve outcomes and reduce disability in patients with relapsing multiple sclerosis. The expert faculty will review the recent science of newer S1P-based therapeutics for the treatment of patients with relapsing multiple sclerosis. Current safety, efficacy and tolerability data for novel S1P therapeutics for the treatment of relapsing multiple sclerosis will be analyzed and clinical relevance debated. The faculty will review how to apply early diagnosis and early intervention therapeutic strategies to reduce brain volume loss and improve patient outcomes.

Target Audience

Neurologists and other healthcare professionals who care for patients with MS

Agenda

I. The Role of Newer S1P-Based Therapeutics for the Treatment of Patients with Relapsing Multiple Sclerosis

II. Clinical Trial Update: Safety, Efficacy, and Tolerability Data for Novel S1P Therapeutics for the Treatment of Relapsing Multiple Sclerosis

III. Clinical Strategies for Early Diagnosis and Early Intervention to Reduce Brain Volume Loss and Improve Patient Disabilities

Learning Objectives

  1. Understand the recent science of newer S1P-based therapeutics for the treatment of patients with relapsing multiple sclerosis
  2. Review the safety, efficacy, and tolerability data for novel S1P therapeutics for the treatment of relapsing multiple sclerosis
  3. Apply early diagnosis and early intervention therapeutic strategies to reduce brain volume loss and improve patient disabilities

Faculty

Fred D. Lublin, MD
Saunders Family Professor of Neurology
Director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Icahn School of Medicine at Mount Sinai
New York, New York

 

Joseph R. Berger, MD
Professor of Neurology
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

 

 

Patricia Coyle, MD
Professor and Interim Chair
Director, MS Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, New York

 

 

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Faculty Relationship Identified With:

Fred D. Lublin, MD

 

Consultant/Advisor: Actelion Pharmaceuticals; Apitope; Atara Biotherapeutics; Biogen; Brainstorm Cell Therapeutics; EMD Serono, Inc.; GW Pharmaceuticals; Innate Immunotherapeutics; Jazz Pharmaceuticals; MedDay Pharmaceuticals; Mapi Pharma; MedImmune, LLC/Viela Bio; Novartis Pharmaceuticals Corporation; Orion Biotechnology; Polpharma Group; Population Council; Receptos, Inc./Celgene Corporation; Roche Group/Genentech Inc.; Sanofi Genzyme; Teva Pharmaceuticals; TG Therapeutics, Inc.
Grant/Research Support: Novartis International AG; Actelion Pharmaceuticals; Biogen Inc.; Sanofi U.S.; NMSS; NIH; Brainstorm Cell Therapeutics
Speaker’s Bureau: Sanofi U.S.

Joseph Berger, MD

Consultant/Advisor: Amgen Inc.; Biogen; Dr. Reddy Labs; EMD Serono. Inc.; Encycle Corporation; Excision Bio; Genetech Inc.; Inhibikase Therapeutics, Inc.; Roche Group; Celgene Corporation; Millennium Pharmaceuticals, Inc.; Takeda Pharmaceuticals; Novartis International AG; Shire Plc; Morphic Therapeutic; Merck & Co; MAPI Pharma
Grant/Research Support: Biogen Inc.; Genentech Inc.; Roche Group

Patricia Coyle, MD

Consultant/Advisor: Accordant; Alexion Pharmaceuticals; Bayer AG; Biogen; Celgene Corporation; EMD Serono, Inc.; Genentech Inc.; Roche Group; GlaxoSmithKline Plc; Mylan N.V.; Novartis International AG; Sanofi Genzyme; TG Therapeutics
Grant/Research Support: Actelion Pharmaceuticals Ltd.; Alkermes Plc; Corrona LLD.; Genentech Inc.; Roche Group; MedDay Pharmaceuticals; NINDS; Novartis International AG; Patient-Centered Outcomes Research Institute

 

Planners and Peer Reviewers

Timothy Hayes, MD, PhD; Nicole Brestowski and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Screen Shot 2018-12-11 at 12.19.42 PM

Credit Designation Statements

AcademicCME designates this live material for a maximum of 1.0 AMA PRA Category 1 CreditTM.

Financial Support

This activity has been supported by an independent educational grant from Celgene Corporation

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Celgene Corporation do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions andcomplete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  • CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
  • CME and CNE credit will be issued appropriate certificate of completion.
  • Others may request a “certificate of completion”.
  1. Learners should claim only the credit commensurate with the extent of their participation in the activity.

CE Inquiries/Special Needs

For all CE inquiries or special needs, please contact [email protected].

BUTTON

Provided by: AcademicCME-web